Investors

TSXV: NRX

From acute injury to functional recovery

Nurexone's mission is to pioneer development of novel, biologic and minimally-invasive treatment for Spinal Cord and Traumatic Brain Injuries

We're developing a nanocarrier - based platform that uses exosomes to deliver specialized therapeutic compounds to the body.

Get Investor Updates

Presentations

nurexone- from acute to functional reconery
nurexone- from acute to functional reconery

Financials

2022

August 25, 2022
Q2 2022 - Quarterly Report
March 31, 2022
CONDENSED INTERIM FINANCIAL STATEMENTS

In THE MEDIA

November 21, 2022
EconoTimes
NurExone announces FDA discussions as they bring hope to millions of spinal cord injury patients
November 16, 2022
LinkedIn
The only thing in our hands is to make a company public